Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib vs Placebo in Advanced Gastric Cancer
NCT02461407Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) comparing Anlotinib with Placebo (2 arms). Primary endpoint: Overall Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02461407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461407.